AOD-9604: the growth hormone fragment and how it works
The name AOD-9604 often comes up in discussions of fat metabolism. Its appeal lies in the idea: taking one small part of growth hormone that relates to fat, without bringing along the other effects of the whole molecule. This article traces the origin of the molecule, how it works, and what was observed in human trials.
A small fragment from the end of growth hormone
Human growth hormone (hGH) is a protein with 191 amino acids. In the 1990s, researchers at Monash University, Australia, observed that the end part of its chain, around amino acids 176 to 191, appeared to play a role in fat metabolism. AOD-9604 is a modified version of that fragment, a 16 amino acid peptide that was later developed by the Australian company Metabolic Pharmaceuticals. The abbreviation AOD comes from anti-obesity drug, which shows its original target.
Why it was separated from the whole molecule
Whole hGH carries many effects at once: it drives tissue growth, raises IGF-1, and affects insulin sensitivity. The idea behind AOD-9604 is to take only its fat metabolism side. Early laboratory research observed that fat breakdown increased and fat formation decreased, with no rise in IGF-1 or blood sugar. Those findings are what took this molecule into human trials, in the form of an infusion as well as an oral tablet. Differences in route of administration like this are covered in peptide dosage forms.
What was observed in human trials
Six randomized, double-blind trials with a comparison group were later summed up in a single safety review published in 2013. That review found no rise in IGF-1, glucose tolerance tests stayed normal, and there were no antibodies against AOD-9604 in the participants examined. The complaints that appeared were on par with the comparison group.
In terms of body weight, an earlier 12-week trial reported a small difference compared with the comparison group, and the trials that followed gave mixed results.
| Stage | What was observed | Notes |
|---|---|---|
| Laboratory research | Fat breakdown rose, IGF-1 unchanged | The basis of the original idea |
| Human safety trials | Complaint profile on par with the comparison group | Summed up in the 2013 review |
| Body weight trials | Results varied between trials | Trials ran for 12 to 24 weeks |
Why AOD-9604 is still in demand
Interest in AOD-9604 has lasted because of its combination: it comes from a natural body hormone, is designed to carry only the fat metabolism side, and has a clean short-term safety profile with no rise in IGF-1. When AOD-9604 is offered together with other ingredients in one package, how to read a combination like that is covered in combining peptides with other active ingredients.
A note for athletes
If you take part in official competition that involves doping tests, AOD-9604 is on the WADA list, so it is best avoided for as long as you are bound by anti-doping rules.
The product details are in the Peptivia catalog. If there is anything you would like to ask before ordering, the Peptivia team is ready to help through Peptivia's official WhatsApp.
